Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
On Jun. 2, 2022, Novavax announced the submission of a request to the Medicines and Healthcare products Regulatory…
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
On May 30, 2022, The Centre for Health Protection (CHP) of the Department of Health received notification from…
On May 25, 2022, Pfizer and BioNTech announced topline safety, immunogenicity and vaccine efficacy data from a Phase…
On May 25, 2022, Novavax announced it was participating in a stage of the COVID-19 Vaccine Schedule Combinations…
On May 21, 2022, the World Health Organization (WHO) reported that since May 13, 2022, cases of mpox…
On May 20, 2022, Novavax announced the submission of a request to the European Medicines Agency (EMA) to…
On May 19, 2022, WHO issued an emergency use listing (EUL) for CONVIDECIA, a vaccine manufactured by CanSino…
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
On May 18, 2022, scientists at the Centers for Disease Control and Prevention (CDC) announced that they were…
On May 13, 2022, Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food…
On May 12, 2022, WHOメs COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement…
On May 12, 2022, the U.S. National Institutes of Health announced that it had licensed 11 COVID-19 research…
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
On May 6, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) announced that it had launched…
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
On Apr. 28, 2022, Centers for Disease Control and Prevention (CDC) reported that a person had tested positive…
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
On Apr. 22, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…
On Apr. 20, 2022, Novavax announced initial results from the Phase 1/2 clinical trial of its COVID-Influenza Combination…
On Apr. 20, 2022, Codiak BioSciences announced new preclinical data from its pan beta-coronavirus vaccine program, which aims…
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
On Apr. 19, 2022, Moderna announced new clinical data on its bivalent COVID-19 booster platform including data on…
On Apr. 18, 2022, the Military Health System reported that active-duty service members who received a COVID-19 vaccine…